![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
Chemical and physical data | |
Formula | C23H36O2 |
Molar mass | 344.539 g·mol−1 |
3D model (JSmol) | |
| |
|
Hexahydrocannabiphorol (HHCP, sometimes mistakenly referred to as hexahydroxycannabiphorol) is a semi-synthetic cannabinoid derivative which has been marketed since around 2021. [1] [2] It is believed to be made from the hydrogenation of tetrahydrocannabiphorol (THCP). THCP is only reported as a trace component of cannabis in 2019. [3] HHCP was studied by Roger Adams as early as 1942. [4]
HHC-P is a partial agonist of the CB1 receptors with an EC50 of 44.4nM for 9R-HHCP and 134nM for 9S-HHCP. Compared to Hexahydrocannabinol (HHC) with an EC50 of 101nM for 9R-HHC and 1,190nM for 9S-HHC [5] In 2021, HHC-P was positively identified in multiple gray market cannabis products in the United States. [1]
The legal status of hexahydrocannabinol and derivatives varies between countries, leading to widespread sale in some parts of Europe and the US.
In France, HHCP was banned in 2023. [6]
In Japan, Japanese Health Ministry announced that six synthetic cannabinoids with structures similar to HHCH, including HHCP, were to be banned from 6 January 2024 [7]
HHCP was banned in Slovakia as of 13 January 2024.[ citation needed ]